Patents for A61P 35 - Antineoplastic agents (221,099)
05/1999
05/06/1999EP0912487A1 Substituted oxobutyric acids as matrix metalloprotease inhibitors
05/06/1999EP0912198A1 Immunoliposomes that optimize internalization into target cells
05/06/1999EP0912196A1 Use of a thexaphyrin in the preparation of a medicament for use with a chemotherapeutic agent in cancer chemosensitization
05/06/1999EP0912192A1 Gm-csf administration for the treatment and prevention of recurrence of brain tumors
05/06/1999EP0912189A1 Use of artichoke (cynara) extracts
05/06/1999EP0912172A1 Combination of cis-4-hydroxy-l-proline and n-methyl-cis-4-hydroxy-l-proline for use as a therapeutic agent, in particular in cancer treatment
05/06/1999EP0912085A1 Precise efficacy assay methods for active agents including chemotherapeutic agents
05/06/1999EP0794953B1 Quinazoline derivatives
05/06/1999EP0785792B1 Treatment of ovarian estrogen dependent conditions
05/06/1999EP0721457B1 2',5'-OLIGOADENYLATE-2',3'-CYCLOPHOSPHATES and 2',5'-OLIGOADENYLATES with antipapilloma virus activity
05/06/1999EP0688315B1 Pyrrolidine and oxazolidine derivatives, their preparation and their use as inhibitors of thrombocyte aggregation
05/06/1999EP0582581B1 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES
05/06/1999EP0570519B1 Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis
05/06/1999EP0563060B1 Use of IL-4 and TNF for the preparation of a medicament for the treatment of tumour cells
05/06/1999CA2308454A1 Antagonists of gonadotropin releasing hormone
05/06/1999CA2308327A1 Sarcodictyin and eleutherobin useful for stabilising microtubules
05/06/1999CA2308069A1 Antagonists of gonadotropin releasing hormone
05/06/1999CA2307830A1 Isolated nucleic acid molecule encoding mammalian endoglucuronidase and uses therefor
05/06/1999CA2307320A1 148 human secreted proteins
05/06/1999CA2306183A1 Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3
05/06/1999CA2306082A1 Substituted 4-amino-thiazol-2-y compounds as cdks inhibitors
05/05/1999CN1216063A IL-6 mutein
05/05/1999CN1216043A Substd. benzenesulfonamide derivs as prodrugs of COX-2 inhibitors
05/05/1999CN1215996A Indications for use as medicaments of multipotent parapox immunity inducers from attenuated, non-immunogenic pox viruses or parapox viruses
05/05/1999CN1215991A Enteric-coated pharmaceutical compositions of mycophenolate
05/05/1999CN1043231C Monohydrate of (E)-alpha-deoxy-alpha-(fluoro-methylene) cytidine
05/04/1999US5900429 Treating breast cancer in mammals by administering taxol or cisplatin to reduce tumor or cancer, then administering 2-methoxycarbonylaminobenzimidazole or pharmaceutical addition salts; anticarcinogenic/antitumor agents
05/04/1999US5900247 Mucoadhesive pharmaceutical composition for the controlled release of active principles
05/04/1999CA2163706C Amino acid derivatives of paclitaxel
05/04/1999CA2078129C O6-benzylated guanine, guanosine and 2'- deoxyguanosine compounds possessing o6-alkylguanine-dna alkyltransferase depleting activity
05/04/1999CA1340527C Macrocyclic complexes of yttrium, the lanthanides and the actinides having peripheral coupling functionalities
04/1999
04/30/1999CA2237419A1 An aglucone isoflavone enriched vegetable protein extract and isolate and process for producing
04/30/1999CA2219867A1 The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
04/29/1999WO1999020794A1 Documentation means for repertoires of nkr immunoreceptors and/or activatory or non-inhibitory immunoreceptor counterparts of nkr immnunoreceptors
04/29/1999WO1999020791A1 Method for suppressing multiple drug resistance in cancer cells
04/29/1999WO1999020758A1 Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
04/29/1999WO1999020755A2 Novel cytokine receptors
04/29/1999WO1999020747A2 HUMAN CHECKPOINT KINASE, hCDS1, COMPOSITIONS AND METHODS
04/29/1999WO1999020656A1 Anti-idiotype monoclonal antibodies, their use in active immunotherapy of malignant tumors and compositions containing them
04/29/1999WO1999020653A1 Low-toxicity human interferon-alpha analog
04/29/1999WO1999020612A1 Imidazole derivatives and their use as farnesyl protein transferase inhibitors
04/29/1999WO1999020611A1 Imidazole derivatives and their use as farnesyl protein transferase inhibitors
04/29/1999WO1999020608A1 Isoquinolines as urokinase inhibitors
04/29/1999WO1999020310A1 J-chain and analogues as epithelial cell targeting conjugates
04/29/1999WO1999020308A1 A method for inhibiting metastasis and tumor cell growth by clinically modulating tumor expression of fas ligand
04/29/1999WO1999020301A1 Tumour vaccine
04/29/1999WO1999020295A1 Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
04/29/1999WO1999020264A1 Formulations and methods for reducing toxicity of antineoplastic agents
04/29/1999WO1999020121A2 Methods for obtaining protein mixtures and control factors from wound granulation, epithelialization or determined blastocyst tissue
04/29/1999WO1998042296A9 Compositions and methods for diagnosing/treating disease based on beta-catenin/transcription factor interactions
04/29/1999CA2308114A1 Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
04/29/1999CA2308013A1 Human checkpoint kinase, hcds1, compositions and methods
04/29/1999CA2307639A1 Tumour vaccine
04/29/1999CA2307342A1 Method for suppressing multiple drug resistance in cancer cells
04/29/1999CA2306953A1 Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
04/29/1999CA2306445A1 Documentation means for repertoires of nkr immunoreceptors and/or activatory or non-inhibitory immunoreceptor counterparts of nkr immunoreceptors
04/29/1999CA2306204A1 J-chain and analogues as epithelial cell targeting conjugates
04/28/1999EP0911633A1 A method of identifying agonists and antagonists for tumor necrosis related receptors TR1, TR3 and TR5
04/28/1999EP0911409A2 Deformylase
04/28/1999EP0911399A2 A kringle-related clone, HTHBZ47
04/28/1999EP0911388A2 Method for stimulation of T-cells with desired antigenspecificity
04/28/1999EP0911319A1 Malonic acid based matrix metalloproteinase inhibitors
04/28/1999EP0911033A2 Methods and compositions for the treatment of diseases with interferon while reducing side effects
04/28/1999EP0910669A1 Isolated nucleic acid molecules which are members of the mage-b family and uses thereof
04/28/1999EP0910655A1 Vaccines for treatment of lymphoma and leukemia
04/28/1999EP0910654A1 Enzyme combinations for destroying proliferative cells
04/28/1999EP0910645A1 A KINASE CAPABLE OF SITE-SPECIFIC PHOSPHORYLATION OF I-kappa-B-alpha
04/28/1999EP0910638A2 Polynucleotide encoding secreted proteins
04/28/1999EP0910571A2 Novel antiangiogenic peptides, polypeptides encoding same and methods for inhibiting angiogenesis
04/28/1999EP0910409A1 Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens
04/28/1999EP0910407A1 Method and composition for reconforming multi-epitopic antigens to initiate an immune response
04/28/1999EP0910387A1 Apoptosis associated protein bbk
04/28/1999EP0910385A1 Sensitization of cells to radiation and chemotherapy
04/28/1999EP0910384A1 Method of inhibiting vascular cell adhesion molecule-1 and treating chronic inflammatory diseases with 2,6-di-alkyl-4-silyl-phenols
04/28/1999EP0910382A1 Treatment of carcinomas using squalamine in combination with other anti-cancer agents
04/28/1999EP0910380A1 Substituted benzylidene indenyl formamides, acetamides and propionamides
04/28/1999EP0910369A1 Benzothiophenes, formulations containing same, and methods
04/28/1999EP0910365A1 Growth inhibition and eradication of solid tumors using neuroendocrine resetting therapy and photodynamic therapy
04/28/1999EP0910357A1 Down-regulation of dna repair to enhance sensitivity to p53-mediated suppression
04/28/1999EP0910246A1 Use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents
04/28/1999EP0784629B1 Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases
04/28/1999EP0779888B1 Pyrimido [5,4-d]pyrimidines, drugs containing these compounds, their use, and process for preparing them
04/28/1999EP0775150B1 Endotoxin reduction or removal process
04/28/1999EP0592480B1 Use of papillomavirus L2 protein for therapeutic treatment of papillomavirus tumours or lesions
04/28/1999EP0585364B1 Ctaa 81av78, the antigen recognized by human monoclonal antibody 81av78
04/28/1999CN1215407A Human antibodies that bind huma TNF 'alpha'
04/28/1999CN1215404A Non-dendritic backbone piptide carrier
04/28/1999CN1215401A 4-(benzo-1,3-dioxolyl)-pyrrolidine-3-carboxylic acid derivatives endothelin antagonists
04/28/1999CN1215396A Novel furan diarylmethylidene derivatives, method for their preparation and therapeutical uses thereof
04/28/1999CN1215333A Use of derivativ
04/28/1999CN1215309A Implantable agarose-collagen beads containing cells which produce a diffusible biological product, and uses thereof
04/28/1999CN1214919A Oral liquid for anti-cancer
04/28/1999CN1043143C Beta, beta-dihydroxy meso-substituted chlorin, bacteriochlorin, isobacteriochlorin and process for making same
04/27/1999US5897871 Therapeutic agent for the treatment of melanomas
04/27/1999US5897862 Immuno-stimulatory monoclonal antibodies
04/27/1999CA2163778C Indole derivatives as steroid 5a-reductase inhibitors
04/27/1999CA2064585C Inhibition of tumor growth by blockade of the protein c system
04/27/1999CA1340513C Antitumor and antiviral alkaloids
04/24/1999CA2248170A1 A clone hwhhj20
04/23/1999CA2239255A1 Cdna clone hneaa81 that encodes a human 7-transmembrane receptor